ReviewCancers2021
Exploring the Potential Role of the Gut Microbiome in Chemotherapy-Induced Neurocognitive Disorders and Cardiovascular Toxicity.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.Annals of medicine · 2026Pooled it
- Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Gallic Acid Attenuates Ifosfamide-Induced Gut Microbiota Dysbiosis: A Full-Length 16S rRNA Amplicon Sequencing Study.Microorganisms · 2026Article
- Review
- Assessing mental health, cognitive function and quality of life of breast cancer patients: exploring associations with gut microbiota in an observational and preliminary study.Frontiers in psychology · 2026Article
- Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment.Current molecular medicine · 2026Review
- The potential of microbiome modulators to improve quality of life in cancer survivors through gut microbiome-immune interactions.Frontiers in molecular neuroscience · 2026Review
- Firmicutes in gut microbiota: hormonal influence on breast cancer in obese individuals.Discover oncology · 2025Review
- Doxorubicin causes cognitive impairment and alters gut microbiota in both male and female juvenile rats.Scientific reports · 2025Article
- Gut microbiota interact with breast cancer therapeutics to modulate efficacy.EMBO molecular medicine · 2025Review
- Immune cell profiling of peripheral blood in long-term testicular germ cell tumor survivors.Frontiers in immunology · 2025Article
- Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy.International journal of molecular sciences · 2024Review
- Article
- Microbiome in Cancer Development and Treatment.Microorganisms · 2023Review
- Exploring the Involvement of Gut Microbiota in Cancer Therapy-Induced Cardiotoxicity.International journal of molecular sciences · 2023Review
- Review
- Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy.Journal for immunotherapy of cancer · 2022Review
- A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse.Microorganisms · 2022Review
- Cognitive impairment persists at least 1 year after juvenile rats are treated with methotrexate.Neuropharmacology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Chemotherapy, targeting not only malignant but also healthy cells, causes many undesirable side effects in cancer patients. Due to this fact, long-term cancer survivors often suffer from late effects, including cognitive impairment and cardiovascular toxicity. Chemotherapy damages the intestinal mucosa and heavily disrupts the gut ecosystem, leading to gastrointestinal toxicity. Animal models and clinical studies have revealed the associations between intestinal dysbiosis and depression, anxiety, pain, impaired cognitive functions, and cardiovascular diseases. Recently, a possible link between chemotherapy-induced gut microbiota disruption and late effects in cancer survivors has been proposed. In this review, we summarize the current understanding of preclinical and clinical findings regarding the emerging role of the microbiome and the microbiota-gut-brain axis in chemotherapy-related late effects affecting the central nervous system (CNS) and heart functions. Importantly, we provide an overview of clinical trials evaluating the relationship between the gut microbiome and cancer survivorship. Moreover, the beneficial effects of probiotics in experimental models and non-cancer patients with neurocognitive disorders and cardiovascular diseases as well as several studies on microbiota modulations via probiotics or fecal microbiota transplantation in cancer patients are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.